STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Co. - BMY STOCK NEWS

Welcome to our dedicated page for Bristol-Myers Squibb Co. news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co. stock.

Bristol-Myers Squibb Co. (BMY) is a renowned American multinational pharmaceutical company headquartered in New York City. As one of the largest pharmaceutical companies globally, Bristol-Myers Squibb (BMS) consistently ranks on the Fortune 500 list. In fiscal 2022, the company achieved total revenue of $46.2 billion.

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs across various therapeutic areas, including cardiovascular, cancer, and immune disorders. A significant area of focus for BMS is immuno-oncology, where it has established itself as a leader in drug development. Approximately 70% of BMS's total sales are derived from the U.S. market, reflecting its higher dependence on this region compared to its peers.

Recent achievements and collaborations highlight BMS's commitment to innovation and partnerships. On May 22, 2024, BMS joined NeoPhore Limited's oversubscribed Series B extension round. This additional investment will enable NeoPhore to explore novel biology associated with the DNA mismatch repair (MMR) pathway in cancer, and further advance its pre-clinical studies. NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.

Another noteworthy collaboration was announced on June 5, 2024, with I-Mab, a U.S.-based global biotech company. This partnership will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody, with BMS's immune checkpoint inhibitor, nivolumab, and chemotherapy. The study, a multi-national Phase 1, will focus on advanced Claudin 18.2-positive gastric and esophageal cancers. BMS will supply nivolumab, which is designed to enhance T-cell function and improve anti-tumor responses.

Additionally, on June 5, 2024, Envisagenics, an AI-driven biotechnology company, announced a Series B fundraising round with participation from BMS. This funding will be utilized to further develop Envisagenics' pipeline of novel preclinical oncology assets using their cloud-based AI drug discovery platform, SpliceCore®. This collaboration underscores BMS's continued investment in innovative technologies and therapeutics.

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. Through strategic partnerships, cutting-edge research, and a commitment to therapeutic advancements, BMS continues to make significant strides in the biopharmaceutical industry.

News

Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...

Rhea-AI Summary
Bristol Myers Squibb (BMY) announced positive results from the Phase 3 CheckMate -8HW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in patients with MSI-H/dMMR metastatic colorectal cancer. The combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, meeting the primary endpoint. The safety profile was manageable with no new safety signals identified.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
clinical trial
-
News

Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization

Rhea-AI Summary
Bristol Myers Squibb (BMY) authorizes an additional $3 billion share repurchase, bringing the total outstanding authorization to approximately $5 billion. The program allows management to execute repurchases at their discretion, based on market conditions and other considerations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
buyback
-
News

Bristol Myers Squibb Announces Dividend Increase

Rhea-AI Summary
Bristol Myers Squibb (BMY) has declared a quarterly dividend of $0.60 per share on its common stock, representing a 5.3% increase over last year's rate. The annual dividend rate for the fiscal year 2024 is $2.40 per share. This marks the 15th consecutive year of dividend increases and the 92nd consecutive year of paying dividends.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
dividends
News

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic...

Rhea-AI Summary
Bristol Myers Squibb (BMY) has announced that the FDA has accepted the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with cisplatin-based chemotherapy as a first-line treatment for adult patients with unresectable or metastatic urothelial carcinoma. The FDA granted the application Priority Review status and assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
News

Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology

Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) partners with Bristol Myers Squibb (BMY) in a global licensing and research collaboration focused on cardiovascular targets. Avidity will receive $100 million upfront with the potential to receive up to $2.2 billion in milestone payments and up to low double-digit royalties. AOCs, Avidity's proprietary RNA therapeutics, will be utilized in the collaboration, expanding the reach of AOCs through the expansion of the existing relationship with Bristol Myers Squibb.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
-
News

Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

Rhea-AI Summary
Bristol Myers Squibb (BMY) and 2seventy bio, Inc. (TSVT) announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) will review data for the sBLA for Abecma for earlier lines of triple-class exposed relapsed or refractory multiple myeloma (RRMM) based on Phase 3 KarMMa-3 study. The ODAC meeting date is pending, and the PDUFA target action date has been extended. The companies await the FDA's decision and anticipate the ODAC to review data related to the secondary endpoint of overall survival (OS). The KarMMa-3 study showed significant improvement in progression-free survival (PFS) and a consistent safety profile of Abecma. Final PFS and interim OS data will be presented at the 2023 ASH Annual Meeting. Regulatory applications for Abecma in earlier lines of therapy are under review in Japan, Europe, and Switzerland.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
none
News

How Is BMS Making Progress on Its Renewable Energy Goals?

Rhea-AI Summary
BMS: Vice President of Sustainability Addresses Key Questions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)

Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) - FDA Approves Augtyro™ (repotrectinib) for ROS1-Positive Non-Small Cell Lung Cancer Treatment - Bristol Myers Squibb announced the FDA approval of Augtyro™ (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Administered as an oral therapy, Augtyro is a tyrosine kinase inhibitor targeting ROS1 oncogenic fusions. The approval is based on the TRIDENT-1 study, showing a high objective response rate and durable response. Augtyro adds to Bristol Myers Squibb’s precision medicine portfolio, expanding the company’s presence in the NSCLC market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
fda approval
-
News

Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030

Rhea-AI Summary
Defence Therapeutics Inc. (OTCPK: DTCFF): Oncology drugs market growth is driven by rising cancer prevalence, new drug launches, and research activities. The global oncology drugs market size is projected to grow from USD 205.52 billion in 2023 to USD 484.32 billion by 2030, exhibiting a CAGR of 13.0%. Defence Therapeutics submitted an Investigational New Drug (IND) application for AccuTOX®, an injectable anticancer molecule, with potential to combat solid tumors. The company aims to advance AccuTOX® into clinical trials, with the primary objective of identifying therapeutic dosing range for co-administration with Opdulag®, a BMS product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
News

Bristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference

Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) to participate in 2023 Jefferies London Healthcare Conference, with Tim Power, VP of investor relations, addressing questions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
conferences

FAQ

What is the current stock price of Bristol-Myers Squibb Co. (BMY)?

The current stock price of Bristol-Myers Squibb Co. (BMY) is $58 as of December 26, 2024.

What is the market cap of Bristol-Myers Squibb Co. (BMY)?

The market cap of Bristol-Myers Squibb Co. (BMY) is approximately 117.3B.

What is Bristol-Myers Squibb's core business?

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs for various therapeutic areas, including cardiovascular, cancer, and immune disorders.

Where is Bristol-Myers Squibb headquartered?

Bristol-Myers Squibb is headquartered in New York City, USA.

What was Bristol-Myers Squibb's revenue for fiscal 2022?

Bristol-Myers Squibb reported a total revenue of $46.2 billion for fiscal 2022.

What is a significant focus area for Bristol-Myers Squibb?

A significant focus area for Bristol-Myers Squibb is immuno-oncology, where it is a leader in drug development.

How much of Bristol-Myers Squibb's total sales come from the U.S. market?

Approximately 70% of Bristol-Myers Squibb's total sales are derived from the U.S. market.

What recent collaboration did Bristol-Myers Squibb announce with NeoPhore Limited?

On May 22, 2024, Bristol-Myers Squibb joined NeoPhore Limited's Series B extension round to explore novel biology associated with the DNA mismatch repair pathway in cancer.

What is the purpose of Bristol-Myers Squibb's collaboration with I-Mab?

The collaboration with I-Mab focuses on evaluating the combination of givastomig with BMS's nivolumab and chemotherapy for advanced Claudin 18.2-positive gastric and esophageal cancers.

What is SpliceCore®?

SpliceCore® is Envisagenics' cloud-based AI drug discovery platform that integrates machine learning algorithms to identify novel and disease-specific RNA splicing isoforms.

When did Bristol-Myers Squibb participate in Envisagenics' Series B fundraising round?

Bristol-Myers Squibb participated in Envisagenics' Series B fundraising round announced on June 5, 2024.

What is Bristol-Myers Squibb's mission?

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.

Stock BMY logo
Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

#108 Ranked by Market Cap
#713 Ranked by Dividends

BMY Stock Data

117.31B
2.03B
0.12%
78.46%
1.27%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
PRINCETON